Document Detail

Neuroprotective effect of combined hypoxia-induced VEGF and bone marrow-derived mesenchymal stem cell treatment.
MedLine Citation:
PMID:  20183925     Owner:  NLM     Status:  MEDLINE    
PURPOSES: To avoid unwanted adverse effects of higher doses of single treatment of stem cells and gene therapy and increase the therapeutic efficacies, we hypothesized the combined therapy with stem cells and gene therapy. This study assessed the neuroprotective effects of combined gene therapy and stem cell treatment under ischemic hypoxia conditions using hypoxia-inducible vascular endothelial growth factor (VEGF) and bone marrow-derived mesenchymal stem cells (BMSC).
METHODS: Experimental groups included the control which was N2A cells transfected with empty vectors, the transfection only group which was N2A cells treated with pEpo-SV-VEGF alone, the BMSC only group which was N2A cells transfected with empty vectors and cocultured with BMSCs, and the combined treatment group which was N2A cells treated with pEpo-SV-VEGF and cocultured with BMSCs. Each group was transfected for 4 h and cultured at 37 degrees C and 5% CO2 for 24 h. Each group was then cultivated under hypoxic conditions (1% O2) for 12 h. Neuroprotective effects were assessed by reverse transcription polymerase chain reaction, annexin V, and cytotoxicity assay.
RESULTS: Neurons exposed to hypoxic conditions exhibited neuronal apoptosis. Compared to single treatments, the combined hypoxia-inducible VEGF and BMSC treatment demonstrated a significant increase in VEGF expression and decreased neuronal apoptosis.
CONCLUSIONS: These results suggest that combined pEpo-SV-VEGF and BMSC treatment is effective in protecting neurons against hypoxic ischemic injury.
Sung Su An; Hong Lian Jin; Keung Nyun Kim; Dong Seok Kim; Joon Cho; Meng-Lu Liu; Jin Soo Oh; Do Heum Yoon; Min Hyung Lee; Yoon Ha
Related Documents :
11788735 - High-level and high-throughput recombinant protein production by transient transfection...
9653145 - Targeted expansion of genetically modified bone marrow cells.
7706765 - Amelioration of the metabolic defect in erythropoietic protoporphyria by expression of ...
19066595 - Microporation is a valuable transfection method for gene expression in human adipose ti...
15576765 - Specialized persister cells and the mechanism of multidrug tolerance in escherichia coli.
93135 - Differences in the susceptibility of mhc and non-mhc mixed lymphocyte reactions to supp...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery     Volume:  26     ISSN:  1433-0350     ISO Abbreviation:  Childs Nerv Syst     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-24     Completed Date:  2010-05-14     Revised Date:  2014-02-21    
Medline Journal Info:
Nlm Unique ID:  8503227     Medline TA:  Childs Nerv Syst     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  323-31     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apoptosis / physiology
Bone Marrow Transplantation*
Cell Hypoxia / physiology
Cell Line, Tumor
Cells, Cultured
Coculture Techniques
Genetic Vectors
Mesenchymal Stem Cell Transplantation*
Neurons / physiology*
Rats, Sprague-Dawley
Vascular Endothelial Growth Factor A / genetics*,  metabolism
Reg. No./Substance:
0/Vascular Endothelial Growth Factor A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Determination of subcellular concentrations of soluble carbohydrates in rose petals during opening b...
Next Document:  Fibrocartilaginous mesenchymoma of the spine in a child: a case report.